117 related articles for article (PubMed ID: 30881017)
1. Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life.
De Luca R; Profita G; Cicero G
Onco Targets Ther; 2019; 12():1621-1627. PubMed ID: 30881017
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer.
De Luca R; Blasi L; Alù M; Gristina V; Cicero G
Drug Des Devel Ther; 2018; 12():1769-1775. PubMed ID: 29950811
[TBL] [Abstract][Full Text] [Related]
3. Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients.
Fabi A; Giannarelli D; Malaguti P; Ferretti G; Vari S; Papaldo P; Nisticò C; Caterino M; De Vita R; Mottolese M; Iacorossi L; Cognetti F
Drug Des Devel Ther; 2015; 9():6177-83. PubMed ID: 26640370
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients.
Xiong W; Xu T; Liu X; Zhang L; Yuan Y
Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397
[TBL] [Abstract][Full Text] [Related]
6. A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer.
Lu H; Zha S; Zhang W; Wang Q; Jiang D; Xu X; Zheng X; Qiu M; Shan C
BMC Cancer; 2021 Jul; 21(1):830. PubMed ID: 34275458
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study evaluating different maintenance schedules of nab-paclitaxel in the first-line treatment of metastatic breast cancer: final results of the IBCSG 42-12/BIG 2-12 SNAP trial.
Gennari A; Sun Z; Hasler-Strub U; Colleoni M; Kennedy MJ; Von Moos R; Cortés J; Vidal MJ; Hennessy B; Walshe J; Parraga KA; Ribi K; Bernhard J; Murillo SM; Pagani O; Barbeaux A; Borstnar S; Rabaglio-Poretti M; Maibach R; Regan MM; Jerusalem G;
Ann Oncol; 2018 Mar; 29(3):661-668. PubMed ID: 29228091
[TBL] [Abstract][Full Text] [Related]
8. ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer.
Koumarianou A; Makrantonakis P; Zagouri F; Papadimitriou C; Christopoulou A; Samantas E; Christodoulou C; Psyrri A; Bafaloukos D; Aravantinos G; Papakotoulas P; Baka S; Andreadis C; Alexopoulos A; Bompolaki I; Kampoli Κ; Liori S; Karvounis K; Ardavanis A
Breast Cancer Res Treat; 2020 Jul; 182(1):85-96. PubMed ID: 32418045
[TBL] [Abstract][Full Text] [Related]
9. Final Effectiveness and Safety Results of NABUCCO: Real-World Data From a Noninterventional, Prospective, Multicenter Study in 697 Patients With Metastatic Breast Cancer Treated With nab-Paclitaxel.
Marschner N; Salat C; Söling U; Hansen R; Grebhardt S; Harde J; Nusch A; Potthoff K
Clin Breast Cancer; 2018 Dec; 18(6):e1323-e1337. PubMed ID: 30100104
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.
Dent S; Fraser J; Graham N; Campbell M; Hopkins S; Dranitsaris G
Curr Oncol; 2013 Feb; 20(1):24-9. PubMed ID: 23443761
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study of Efficacy and Safety of Albumin-Bound Paclitaxel in Metastatic Breast Cancer.
Singh RK; Pankaj S; Kumar S; Rajkota V
World J Oncol; 2014 Dec; 5(5-6):204-209. PubMed ID: 29147404
[TBL] [Abstract][Full Text] [Related]
12. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
13. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
15. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis.
Liang C; Li L; Fraser CD; Ko A; Corzo D; Enger C; Patt D
BMC Cancer; 2015 Dec; 15():1019. PubMed ID: 26714468
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
[TBL] [Abstract][Full Text] [Related]
17. Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Miyagawa Y; Araki K; Bun A; Ozawa H; Fujimoto Y; Higuchi T; Nishimukai A; Kira A; Imamura M; Takatsuka Y; Miyoshi Y
Clin Breast Cancer; 2018 Oct; 18(5):400-409. PubMed ID: 29605174
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study.
Vernieri C; Milano M; Mennitto A; Maggi C; Ferrari B; Rinaldi L; Mennitto R; Stefanetti C; Re B; Mariani G; Bianchi G; Capri G; de Braud F
Breast Cancer Res Treat; 2017 Sep; 165(2):365-373. PubMed ID: 28616768
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer.
Sun S; Tang L; Zhang J; Lv F; Wang Z; Wang L; Zhang Q; Zheng C; Qiu L; Jia Z; Lu Y; Liu G; Shao Z; Wang B; Hu X
Int J Nanomedicine; 2014; 9():1443-52. PubMed ID: 24672237
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R
Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
